Valion Bio, Inc.
VBIO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.94
KIRA · Stoqly’s AI analyst, in plain words
- Valion Bio, Inc. lost $8.9M in fiscal 2025.
- Free cash flow was −$7.0M in fiscal 2025, — of revenue.
Market cap
—
P/E
—
Revenue
—
Net income
−$8.9M
Free cash flow
−$7.0M
Operating margin
—
Valion Bio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$8.9M
No. It lost money last year.
What Valion Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Valion Bio, Inc.
- CIK
- 0001787740
Valion Bio, Inc. · VBIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.3M | $1.8M | $1.2M | $0.8M | — |
| Revenue growth | — | 46.4% | −36.1% | −33.7% | — |
| Net interest income | −$1.8M | $0.0M | $0.0M | $0.0M | — |
| Gross margin | −3.0% | 16.3% | 24.4% | 0.3% | — |
| Operating margin | −448.1% | −548.8% | −701.1% | −573.8% | — |
| Net income | −$8.5M | −$10.1M | −$8.2M | −$5.7M | −$8.9M |
| Net margin | −675.7% | −548.7% | −701.0% | −725.0% | — |
| Diluted EPS | −$2.43 | −$104.32 | −$176.80 | −$19.68 | — |
| Cash | |||||
| Cash from operations | −$5.6M | −$8.9M | −$8.5M | −$5.7M | −$7.0M |
| Capital expenditure | — | $0.0M | $0.1M | $0.0M | $0.0M |
| Free cash flow | — | −$8.9M | −$8.6M | −$5.7M | −$7.0M |
| FCF margin | — | −485.3% | −733.8% | −734.0% | — |
| Share count change | — | −97.2% | −51.8% | 515.4% | — |
| Debt and strength | |||||
| Cash and short-term investments | $13.0M | $3.5M | $3.4M | $2.0M | $12.6M |
| Shareholders' equity | $13.3M | $3.6M | $3.6M | $2.5M | $16.8M |
| Current ratio | 11.7x | 2.8x | 3.3x | 9.7x | 20.1x |
| Interest coverage | — | — | — | — | −54.1x |
| Returns and quality | |||||
| Return on equity | −64.0% | −119.5% | −228.7% | −185.0% | −91.8% |
| Return on tangible equity | −64.0% | −278.1% | −230.3% | −223.1% | −80.0% |
| Piotroski F-score | — | 4 | 4 | 2 | — |
| Altman Z'' | 6.8 | −22.5 | −28.2 | −46.0 | −2.2 |
Insiders bought, 12 months
$0.0M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Valion Bio, Inc. · VBIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.94 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001787740). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.